Development of Long-Acting Treatments for HCV Cure
ID: NIH/NIAID 125Type: BOTH
Overview

Topic

Development of Long-Acting Treatments for HCV Cure

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451727

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for the development of long-acting treatments for HCV cure. The goal is to address the global issue of chronic hepatitis C virus (HCV) infection, which affects an estimated 58 million people worldwide. The solicitation aims to support research that can provide a one-dose alternative to cure HCV infection, potentially overcoming challenges related to access to diagnosis and treatment, as well as compliance with multiple drug regimens. The anticipated awards include 2-3 projects, with a budget of $300,000 for Phase I (up to 2 years) and $1 million for Phase II (up to 3 years). The development of long-acting treatments for HCV could simplify test and treat strategies, reduce healthcare infrastructure needs, and mitigate concerns about drug resistance. Ultimately, these treatments could contribute to the eradication of Hepatitis C.

Files
No associated files provided.
Similar Opportunities
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of medications to treat Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with strong background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. The research objectives include advancing small molecules, natural products, and biologics through pre-clinical development, IND-enabling toxicology, and clinical development phases. The program emphasizes the importance of adherence to compliance and quality criteria, including Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Intellectual property development and retention is strongly encouraged, and applications that focus on animal model development, basic research, or activities already funded by other sources will not be considered. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html).
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the investigational new drug (IND)-enabling and early-stage development of medications to treat alcohol use disorder (AUD) and alcohol-associated organ damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with robust background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html).
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of medications to treat Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with strong background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html).
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the investigational new drug (IND)-enabling and early-stage development of medications to treat alcohol use disorder (AUD) and alcohol-associated organ damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should have a robust body of background data in the basic science and early discovery phases and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html).